ABUS (Arbutus Biopharma Corporation Common Stock) Stock Analysis - News
Arbutus Biopharma Corporation Common Stock (ABUS) is a publicly traded Healthcare sector company. As of May 20, 2026, ABUS trades at $4.36 with a market cap of $823.73M and a P/E ratio of 5.20. ABUS moved +3.81% today. Year to date, ABUS is -7.22%; over the trailing twelve months it is +36.14%. Its 52-week range spans $2.71 to $5.10. Rallies surfaces ABUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in ABUS news today?
Moderna Q1 Revenue Triples to $389M with $311M International COVID Sales: Moderna’s Q1 revenue rose to $389 million, more than tripling year-over-year and topping the $228 million consensus, driven by $311 million in international COVID vaccine sales versus $78 million domestically. The company reported a $3.40 per-share net loss, beating the $3.96 expected, despite a $0.9 billion litigation charge, while R&D and SG&A expenses fell 24% and 18%, respectively.
HASTINGS DAVID C sold 22.18K (~$72.83K) on Feb 4, 2025.
Sims Karen sold 19.35K (~$63.52K) on Feb 4, 2025.
McElhaugh Michael J. sold 23.79K (~$78.10K) on Feb 4, 2025.
ABUS Analyst Consensus
ABUS analyst coverage data. Average price target: $0.00.
Common questions about ABUS
What changed in ABUS news today?
Moderna Q1 Revenue Triples to $389M with $311M International COVID Sales: Moderna’s Q1 revenue rose to $389 million, more than tripling year-over-year and topping the $228 million consensus, driven by $311 million in international COVID vaccine sales versus $78 million domestically. The company reported a $3.40 per-share net loss, beating the $3.96 expected, despite a $0.9 billion litigation charge, while R&D and SG&A expenses fell 24% and 18%, respectively.
Does Rallies summarize ABUS news?
Yes. Rallies summarizes ABUS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is ABUS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ABUS. It does not provide personalized investment advice.
